Quantcast

Latest tumour Stories

2011-04-18 14:31:37

Cancer researchers at the University of Calgary are investigating a new tool to use for the prognosis of breast cancer in patients. This new digital tool will help give patients a more accurate assessment of how abnormal and aggressive their cancer is and help doctors recommend the best treatment options. Currently, a useful factor for deciding the best treatment strategy for early-stage breast cancer is tumour grade, a score assigned by a pathologist based on how abnormal cancer cells from a...

2011-04-11 17:03:17

Targeted photodynamic therapy can completely eradicate some models of cancer, according to the latest research by UK and Swiss scientists, published in the current issue of the British Journal of Cancer. The team "“ including researchers from the University of Hull and ETH Zurich "“ linked light-sensitive molecules with antibodies that target tumour blood vessels. When irradiated with light, the molecules create particles known as reactive oxygen species, which in high numbers...

2011-04-06 06:30:00

MELBOURNE, Australia, April 6, 2011 /PRNewswire/ -- Circadian Technologies (ASX.CIR) announced today that its licensee ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company, has advised that it has commenced the first Phase 1 clinical trial of its fully-human monoclonal antibody IMC-3C5. IMC-3C5 is a fully-human IgG1 monoclonal antibody being developed by ImClone as a treatment for cancer. ImClone has exclusive rights from Circadian's 100%-owned subsidiary Vegenics to...

2011-04-06 06:30:00

MELBOURNE, Australia , April 6, 2011 /PRNewswire/ -- Data demonstrates efficacy of VGX-100 with other therapeutic agents in mouse models of lung, ovarian and prostate cancers. VGX-100 improves the efficacy of Avastin® in a lung cancer model and further inhibits tumour growth when combined with Avastin® plus docetaxel in mouse models of human lung and ovarian cancer. Data expand on previous anti-cancer effects seen with VGX-100 in prostate, pancreatic...

2011-04-04 05:05:00

CRAIGAVON, Northern Ireland, April 4, 2011 /PRNewswire/ -- - Scientists at Almac and Queen's University Belfast Discover Novel Approach to Treat Cancer Patients New Study findings published in Clinical Cancer Research - The Journal of the American Association of Cancer Research (AACR) Scientists from the School of Pharmacy at Queen's University Belfast and Almac Discovery Ltd, announce the first publication describing a potential new anti-angiogenic therapy based on a...

2011-03-28 10:00:00

Preliminary analysis shows treatment is well-tolerated and consistently delivered to patients with metastatic liver cancer OTTAWA, March 28 /PRNewswire-FirstCall/ - Nordion Inc. (TSX: NDN) (NYSE: NDZ), a leading provider of products and services to the global health science market, today shared results from the first multi-site, Phase II clinical trial to evaluate TheraSphere® for treatment of metastatic liver cancer. The trial evaluated a variety of factors,...

2011-03-17 20:18:18

Scientists at IRB Barcelona report new data in support of link between stem cells and cancer, opening door to new tools for diagnosis and treatment Colorectal cancer cells trigger a set of genes similar to those found in intestinal stem cells, scientists at the Institute for Research in Biomedicine (IRB Barcelona) have found. The team of researchers, led by ICREA researcher Eduard Batlle, propose that patients with colorectal cancer undergo genetic tests of their intestinal epithelium in...

2011-03-15 02:00:00

OXFORD, England, March 15, 2011 /PRNewswire-FirstCall/ -- - Immune Response Surrogate Algorithm Shownto be a Significant Predictor of Clinical Benefit Oxford BioMedica plc ("Oxford BioMedica" or "the Company") (LSE: OXB), a leading gene therapy company, today announces that further analyses of the TroVax(R) Renal Immunotherapy Survival Trial ("TRIST"), a randomised, double-blind, placebo-controlled Phase III study, have been accepted for publication in Cancer Immunology,...

2011-01-31 15:56:35

Cancer researchers have discovered an important protein, produced naturally inside cells, that appears to suppress the growth of prostate cancer cells in the laboratory. The findings, published tomorrow in the journal Cancer Research, offer promising leads for research towards new treatments. Prostate cancer is the most common cancer among men in the UK, with 37,500 men diagnosed with the disease every year. Many prostate cancers are slow growing, but in some cases the cancer is aggressive...

2011-01-20 22:06:25

A curious contagious cancer, found in dogs, wolves and coyotes, can repair its own genetic mutations by adopting genes from its host animal, according to a new study in the journal Science. Scientists at Imperial College London have uncovered an unusual process that helps the cancer survive by stealing tiny DNA-containing 'powerhouses' (known as mitochondria) from the cells of the infected animal, to incorporate as its own. They say this may be because genes in the tumour's own mitochondria...


Word of the Day
drawcansir
  • A blustering, bullying fellow; a pot-valiant braggart; a bully.
This word is named for Draw-Can-Sir, a character in George Villiers' 17th century play The Rehearsal.
Related